Navigation Links
Dr. Susan Froshauer to join Connecticut bioscience team at CURE
Date:2/12/2013

HARTFORD, Conn., Feb. 12, 2013 /PRNewswire/ -- Peter R. Farina , Ph.D. and David W. Keiser , the two co-chairs of CURE (Connecticut United for Research Excellence), the state bioscience organization, today released the following statement about organizational changes at CURE.

After ten years at the helm, Paul Pescatello , the current President and CEO of CURE, has decided to step back from that role so that he can dedicate some additional time to private business ventures and other non-life sciences policy issues. Paul has made great strides for CURE and so we are pleased to report that he has agreed to continue to coordinate our government relations efforts as Chair of the CURE BioScience Growth Council and as a CURE Board and Executive Committee member. This arrangement will allow Paul to bring even greater focus and depth to CURE's life sciences advocacy.

The state has recently increased its investment in the life sciences and in entrepreneurship. For example, it has invited The Jackson Laboratory to develop a genomic medicine facility in Farmington and created Connecticut's Innovation Ecosystem, a public-private partnership, with hubs in Hartford, New Haven, Stamford and Storrs, to support high-value technology-based start-up and stage 2 companies. Furthermore, Governor Malloy has proposed a new $200 million Bioscience Innovation Act and announced a $1.5 million investment in UConn to support STEM (Science, Technology, Engineering and Math) education activities.

CURE seeks to strengthen and enhance its mission to support these efforts. To do so most effectively, and build on Paul's success, it is our great pleasure to announce that a good friend of the Connecticut life sciences community, Dr. Susan Froshauer , has agreed to assume the position of Chief Executive Officer and President of CURE, effective April 1. Susan is well-known to the CURE community and has a wealth of experience that makes her an ideal choice to lead the organization.

Susan is an experienced scientist, mentor, entrepreneur and investor with skill at connecting academic expertise and technology with the commercial sector. She is currently Director of the Technology Exchange Portal at the University of Connecticut's Office of Economic Development.  In this role Susan assists Connecticut-based entrepreneurs and organizations with initiatives that train students, create jobs and contribute to economic development. She connects ideas with business expertise, business plans with investors and industry with scholars.

Until 2010, Susan served as President and CEO of Rib-X Pharmaceuticals, which she co-founded in New Haven in 2000. Under her leadership, Rib-X raised more than $160 million in private equity, bridge financing and government grants and built a robust pipeline of antibiotics to treat serious hospital infections. Prior to Rib-X, Susan served as a member of Pfizer's Strategic Alliance Group where she was key to the creation of a $200 million investment portfolio that transformed the Pfizer global research and development strategy, helping the company identify new resources for drug discovery.

Susan received a Ph.D. in Microbiology and Molecular Genetics from Harvard University and a B. A. from Connecticut College. She performed post-doctoral research at Yale Medical School in the Department of Cell Biology as a Jane Coffin Child 's Fellow.

Susan will initially focus on expanding the CURE network, fostering connectivity among members, educators, investors and entrepreneurs, helping to build the bridges necessary to transform cutting edge bioscience research into funded, sustainable start-up biotechs as well as fortifying CURE's commitment to education.

Please join us in welcoming Susan and thanking Paul for his decade of CURE leadership. The combined team of Susan and Paul will strengthen and enhance CURE and its work on behalf of CURE members.

Photo of Paul Pescatello : http://curenet.org/photos/PaulPescatello.jpg
Photo of Dr. Susan Froshauer : http://curenet.org/photos/Susan Froshauer.jpg

Contact:
Bill Kelly
HarveyMalis Communications LLC
203-375-2696


'/>"/>
SOURCE CURE (Connecticut United for Research Excellence)
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Connecticut Radiology Group Leverages MedInformatix RIS to Achieve Stage 1 Meaningful Use Objectives
2. Medbox, Inc. Rides a Wave of Local Media Support in Connecticut
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
5. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
6. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
7. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
8. Amarantus BioScience Secures an Additional $1.4 Million in Financing Commitments
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Congresswoman Barbara Lee Visits Tethys Bioscience
11. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
(Date:9/13/2017)... 13, 2017   OrthoAtlanta has been named the ... Host Committee (AFHC) for the 2018 College Football Playoff (CFP) ... at Mercedes-Benz Stadium in Atlanta, Georgia . ... "I,m In" campaign, participating in many activities leading up to, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
Breaking Medicine News(10 mins):